Advertisement

 

 

[Immune checkpoint inhibitors and endocrinological side effects].

[Immune checkpoint inhibitors and endocrinological side effects].
Author Information (click to view)

Jørgensen LB, Bastholt L, Yderstræde K,


Jørgensen LB, Bastholt L, Yderstræde K, (click to view)

Jørgensen LB, Bastholt L, Yderstræde K,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Ugeskrift for laeger 179(49) pii

Abstract

Immune checkpoint inhibitors including anti-cytotoxic T-lymphocyte-associated antigen-4 and anti-programmed cell death-1 have revolutionized cancer therapy but have also induced serious immune-related adverse events including hormonal dysfunction. The objective of this review is to characterize the incidence, clinical presentation, management and prognosis of the endocrine-related adverse events including hypophysitis, thyroid dysfunction and diabetes mellitus. Combination therapy is associated with an increased risk of adverse events. We recommend close monitoring of the hormone levels and glycaemic status during and a year after treatment.

Submit a Comment

Your email address will not be published. Required fields are marked *

20 − 3 =

[ HIDE/SHOW ]